{"id":"W2081213854","doi":"10.1097/01.jto.0000283780.87833.c2","title":"P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Newfoundland and Labrador Centre for Applied Health Research; University of Calgary","funders":"","keywords":"Nimotuzumab; Medicine; Radiation therapy; Oncology; Internal medicine; Toxicity; Phases of clinical research; Epidermal growth factor receptor; Chemotherapy; Progressive disease; Lung cancer; Clinical trial; Gastroenterology; Cancer; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001722567,0.002066276,0.001982936,0.0004388244,0.0005065652,0.00117669,0.001076869,0.001404282,0.003735134],"category_scores_gemma":[0.001031585,0.0005601809,0.001722539,0.0005681725,0.001377475,0.001047931,0.0004793891,0.004956109,0.00101533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009726162,"about_ca_system_score_gemma":0.001698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002269388,"about_ca_topic_score_gemma":0.005742989,"domain_scores_codex":[0.9995611,0.0001876543,0.00001668342,0.00006392146,0.00003622947,0.0001343418],"domain_scores_gemma":[0.9994045,0.0001225026,0.00007525132,0.00004927605,0.00002410925,0.0003242903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6719219,0.08558396,0.007493685,0.0006105026,0.001724467,0.0004957558,0.0006263714,0.006103169,0.05802308,0.0005307343,0.01006865,0.1568177],"study_design_scores_gemma":[0.5998212,0.3713778,0.01604963,0.00003038296,0.0006423212,0.0003902308,0.0000914609,0.002295817,0.005343231,0.0005046149,0.003406841,0.00004662669],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925141,0.0009674364,0.0005609682,0.0008749541,0.0001187104,0.001200635,0.001256212,0.000161088,0.002345906],"genre_scores_gemma":[0.9869676,0.001443333,0.002150119,0.001172213,0.0001915373,0.001721844,0.003226238,0.0001089654,0.003018059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003735134,"threshold_uncertainty_score":0.01249522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04126305062594569,"score_gpt":0.4926962457130592,"score_spread":0.4514331950871135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}